Service
Liquid Biopsy
cfDNA sequencing from plasma to detect mutations, monitor treatment response, and guide precision oncology
Key advantages
Non-invasive alternative to tissue biopsy for tumor genotyping
Real-time monitoring of tumor evolution and treatment resistance
High sensitivity for detecting low-frequency variants in circulating tumor DNA (ctDNA)
Enables longitudinal sampling for disease tracking over time
Supports detection of SNVs, CNVs, fusions, and methylation changes
Applicable to multiple cancers including lung, breast, colorectal, and prostate
Ideal when tissue is unavailable or insufficient for traditional sequencing
Compatible with WGS, WES, targeted panels, and epigenetic assays
Technical specifications
Sample type: plasma (cfDNA extraction)
Sequencing type: targeted panels, WES, WGS, methylation-based assays
Variant detection: SNVs, Indels, CNVs, gene fusions, methylation signatures
Data analysis: tumor fraction estimation, variant allele frequency, mutation tracking
Bioinformatics pipeline: noise suppression, ctDNA-specific alignment, clonal evolution inference
Instruments: MGI DNBSEQ, Illumina NovaSeq, or equivalent NGS platforms
Output files: FASTQ, BAM, VCF, annotated reports, longitudinal dashboards
Use cases: therapy monitoring, MRD detection, recurrence tracking, cancer screening
Secure delivery: GDPR-compliant interactive platform with optional clinical reporting